Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RANOLAZINE

All products: not a benefit

Other products in the same Health Canada class (C01EB) — coverage varies; not interchangeable

  • Ivabradine (Lancora): limited Use 538

Corzyna · DIN 02510219 · 500mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Corzyna · DIN 02510219 Manufacturer: KYE Pharmaceuticals Inc.; listing date 2026-06-30 Health Canada: Marketed since 2021-05-03 · brand CORZYNA · ATC C01EB18 RANOLAZINE · form Tablet (extended-release) · route Oral · ingredients RANOLAZINE 500 MG · company Kye pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Corzyna: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99945 · Verify on the e-Formulary ↗ (DIN 02510219)

Source record
DIN 02510219: Corzyna Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240492007; group id 294; item number 0637; lccId None; manufacturer id KYE Source form: ER Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02510219 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99945
Interchangeable products
Mar-Ranolazine XR · DIN 02562448 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (24:00 CARDIOVASCULAR DRUGS) and how they are covered

Matched class: 24:00 CARDIOVASCULAR DRUGS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATENOLOL, ATORVASTATIN CALCIUM, BEZAFIBRATE, CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, DIGOXIN, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, PROPAFENONE HCL, ROSUVASTATIN CALCIUM, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, BISOPROLOL FUMARATE, CAPTOPRIL, CHOLESTYRAMINE RESIN, CILAZAPRIL, CLONIDINE HCL, COLESEVELAM HYDROCHLORIDE, DILTIAZEM HCL, DISOPYRAMIDE, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FENOFIBRATE, FLECAINIDE ACETATE, FLUVASTATIN SODIUM, FOSINOPRIL SODIUM, GEMFIBROZIL, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, ISOSORBIDE DINITRATE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, LOVASTATIN, METHYLDOPA, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, NITROGLYCERIN, PINDOLOL, PRAVASTATIN SODIUM, PRAZOSIN HCL, PROPRANOLOL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, SIMVASTATIN, SOTALOL HCL, TERAZOSIN HCL, TIMOLOL MALEATE, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

FINERENONE

· 2 products · Limited Use, codes 700 · strengths: 10mg, 20mg · Tab

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

IVABRADINE HCL

· 2 products · Limited Use, codes 538 · strengths: 5mg, 7.5mg · Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 90 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications CORZYNA (ranolazine extended-release tablets) is indicated, as add-on therapy, for symptomatic treatment of adult patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers. 1.1. Pediatrics Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (≥75 years): Evidence from clinical studies suggests that use of ranolazine in patients 75 years of age or older is associated with an increased incidence of adverse events (see 7.1.4 Geriatrics and 8.5 Post-Market Adverse Reactions). https://pdf.hres.ca/dpd_pm/00080946.PDF PM date: 2025-06-30 Source product: CORZYNA; DIN 02510219; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Corzyna: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026